A minimal pbpk/pd model with expansion-enhanced target-mediated drug disposition to support a first-in-human clinical study design for a flt3l-fc molecule

HIGHLIGHTS

• What: In the figures, the authors show cDC1 and total DC, which is the sum of cDC1 and cDC2. The model was able to capture serum plasma levels in ADA-negative samples, which provided confidence in the predictive capabilities of the PK model for nonclinical species. The model simulations successfully reproduced clinical CDX-301 PK and captured the dynamics and dose-dependent saturable expansion of cDC1 and total DC counts reasonably well across both studies . Once the model captures the PK across different dose levels, the exposure can be used as the key driver of expansion for . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.